Skip to main content
Erschienen in: Clinical and Translational Oncology 10/2019

14.02.2019 | Research article

Seven genes for the prognostic prediction in patients with glioma

verfasst von: G.-H. Zhang, Q.-Y. Zhong, X.-X. Gou, E.-X. Fan, Y. Shuai, M.-N. Wu, G.-J. Yue

Erschienen in: Clinical and Translational Oncology | Ausgabe 10/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Glioma is a common malignant tumor of the central nervous system, which is characterized by a low cure rate, high morbidity, and high recurrence rate. Consequently, it is imperative to explore some indicators for prognostic prediction in glioma.

Methods

We obtained glioma data from The Cancer Genome Atlas (TCGA). Differentially expressed genes (DEGs) were obtained by R software from TCGA data sets. Through Cox regression analysis, risk scores were obtained to assess the weighted gene-expression levels, which could predict the prognosis of patients with glioma. The validity and the prognostic value of this model in glioma were confirmed by the manifestation of receiver-operating characteristic (ROC) curves, area under the curve (AUC), and 5-year overall survival (OS).

Results

In total, 920 DEGs of transcriptome genes in glioma were extracted from the TCGA database. We identified a novel seven-gene signature associated with glioma. Among them, AL118505.1 and SMOC1 were positively related to the 5-year OS of patients with glioma, showing a better prognosis for glioma; however, RAB42, SHOX2, IGFBP2, HIST1H3G, and IGF2BP3 were negatively related to 5-year OS, displaying a worse prognosis. In addition, according to risk scores, AL118505.1 was also a protective factor, while others were risk factors. Furthermore, the expression levels of SHOX2, IGFBP2, and IGF2BP3 were significantly positively correlated with glioma grades. Receiver-operating characteristic (ROC) curve assessed the accuracy and sensitivity of the gene signature. Each of the seven genes for patients with the distribution of the risk score was presented in the heat map.

Conclusion

We identified a novel seven-gene signature in patients with glioma, which could be used as a predictor for the prognosis of patients with glioma in the future.
Literatur
1.
Zurück zum Zitat Li B, et al. The accuracy of survival time prediction for patients with glioma is improved by measuring mitotic spindle checkpoint gene expression. PLoS One. 2011;6:e25631.CrossRef Li B, et al. The accuracy of survival time prediction for patients with glioma is improved by measuring mitotic spindle checkpoint gene expression. PLoS One. 2011;6:e25631.CrossRef
2.
Zurück zum Zitat Brandes AA, et al. Temozolomide as a second line systemic regimen in recurrent high—grade glioma a phase II study. Ann Oncol. 2001;129:255.CrossRef Brandes AA, et al. Temozolomide as a second line systemic regimen in recurrent high—grade glioma a phase II study. Ann Oncol. 2001;129:255.CrossRef
3.
Zurück zum Zitat Khasraw M, et al. Antiangiogenic therapy for high-grade glioma. Cochrane Datab Syst Rev. 2014;9:CD008218. Khasraw M, et al. Antiangiogenic therapy for high-grade glioma. Cochrane Datab Syst Rev. 2014;9:CD008218.
4.
Zurück zum Zitat Omar AI. Tumor treating field therapy in combination with bevacizumab for the treatment of recurrent glioblastoma. J Vis Exp. 2014;92:e51638. Omar AI. Tumor treating field therapy in combination with bevacizumab for the treatment of recurrent glioblastoma. J Vis Exp. 2014;92:e51638.
6.
Zurück zum Zitat Louis DN, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131:803–20.CrossRefPubMed Louis DN, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131:803–20.CrossRefPubMed
7.
Zurück zum Zitat Turkalp, et al. IDH mutation in glioma: new insights and promises for the future. JAMA Neurol. 2014;71:1319–25.CrossRefPubMed Turkalp, et al. IDH mutation in glioma: new insights and promises for the future. JAMA Neurol. 2014;71:1319–25.CrossRefPubMed
8.
Zurück zum Zitat Akagi Y, et al. Reclassification of 400 consecutive glioma cases based on the revised 2016 WHO classification. Brain Tumor Pathol. 2018;35:81–9.CrossRefPubMed Akagi Y, et al. Reclassification of 400 consecutive glioma cases based on the revised 2016 WHO classification. Brain Tumor Pathol. 2018;35:81–9.CrossRefPubMed
9.
Zurück zum Zitat Zacher A, et al. Molecular diagnostics of gliomas using next generation sequencing of a glioma-tailored gene. Panel Brain Pathol. 2017;27:146–59.CrossRefPubMed Zacher A, et al. Molecular diagnostics of gliomas using next generation sequencing of a glioma-tailored gene. Panel Brain Pathol. 2017;27:146–59.CrossRefPubMed
10.
Zurück zum Zitat Li B, et al. CD133 in brain tumor: the prognostic factor. Oncotarget. 2017;8:11144–59.PubMed Li B, et al. CD133 in brain tumor: the prognostic factor. Oncotarget. 2017;8:11144–59.PubMed
11.
Zurück zum Zitat Lu G, et al. Phospholipase C Beta 1: a candidate signature gene for proneural subtype high-grade. Glioma Mol Neurobiol. 2016;53:6511–25.CrossRefPubMed Lu G, et al. Phospholipase C Beta 1: a candidate signature gene for proneural subtype high-grade. Glioma Mol Neurobiol. 2016;53:6511–25.CrossRefPubMed
12.
Zurück zum Zitat Song WS, et al. Sox2, a stemness gene, regulates tumor-initiating and drug-resistant properties in CD133-positive glioblastoma stem cells. J Chin Med Assoc. 2016;79:538–45.CrossRefPubMed Song WS, et al. Sox2, a stemness gene, regulates tumor-initiating and drug-resistant properties in CD133-positive glioblastoma stem cells. J Chin Med Assoc. 2016;79:538–45.CrossRefPubMed
14.
Zurück zum Zitat Mancini C, et al. A fetal case of microphthalmia and limb anomalies with abnormal neuronal migration associated with SMOC1 biallelic variants. Eur J Med Genet. 2018;S1769–7212:30397–8. Mancini C, et al. A fetal case of microphthalmia and limb anomalies with abnormal neuronal migration associated with SMOC1 biallelic variants. Eur J Med Genet. 2018;S1769–7212:30397–8.
15.
Zurück zum Zitat Blaschke RJ, et al. SHOT, a SHOX-related homeobox gene, is implicated in craniofacial, brain, heart, and limb development. Proc Natl Acad Sci USA. 1998;95:2406–11.CrossRefPubMedPubMedCentral Blaschke RJ, et al. SHOT, a SHOX-related homeobox gene, is implicated in craniofacial, brain, heart, and limb development. Proc Natl Acad Sci USA. 1998;95:2406–11.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Clement-Jones M, et al. The short stature homeobox gene SHOX is involved in skeletal abnormalities in Turner syndrome. Hum Mol Genet. 2000;9:695–702.CrossRefPubMed Clement-Jones M, et al. The short stature homeobox gene SHOX is involved in skeletal abnormalities in Turner syndrome. Hum Mol Genet. 2000;9:695–702.CrossRefPubMed
17.
18.
Zurück zum Zitat Dietrich D, et al. DNA methylation of the homeobox genes PITX2 and SHOX2 predicts outcome innon-small-cell lung cancer patients. Diagn Mol Pathol. 2012;21:93–104.CrossRefPubMed Dietrich D, et al. DNA methylation of the homeobox genes PITX2 and SHOX2 predicts outcome innon-small-cell lung cancer patients. Diagn Mol Pathol. 2012;21:93–104.CrossRefPubMed
19.
Zurück zum Zitat Yang T, et al. Elevated SHOX2 expression is associated with tumor recurrence of hepatocellular carcinoma. Ann Surg Oncol. 2013;20:S644–9.CrossRefPubMed Yang T, et al. Elevated SHOX2 expression is associated with tumor recurrence of hepatocellular carcinoma. Ann Surg Oncol. 2013;20:S644–9.CrossRefPubMed
20.
Zurück zum Zitat Hong S, et al. SHOX2 is a direct miR-375 target and a novel epithelial-to-mesenchymal transition inducer in breast cancer cells. Neoplasia. 2014;16:e1–5.CrossRef Hong S, et al. SHOX2 is a direct miR-375 target and a novel epithelial-to-mesenchymal transition inducer in breast cancer cells. Neoplasia. 2014;16:e1–5.CrossRef
22.
Zurück zum Zitat Wang H, et al. Insulin-like growth factor-binding protein 2 and 5 are differentially regulated in ovarian cancer of different histologic types. Mod Pathol. 2006;19:1149–56.CrossRefPubMed Wang H, et al. Insulin-like growth factor-binding protein 2 and 5 are differentially regulated in ovarian cancer of different histologic types. Mod Pathol. 2006;19:1149–56.CrossRefPubMed
23.
Zurück zum Zitat Wang Y, et al. IGFBP2 enhances adipogenic differentiation potentials of mesenchymal stem cells from Wharton’s jelly of the umbilical cord via JNK and Akt signaling pathways. PLoS One. 2017;12:e0184182.CrossRefPubMedPubMedCentral Wang Y, et al. IGFBP2 enhances adipogenic differentiation potentials of mesenchymal stem cells from Wharton’s jelly of the umbilical cord via JNK and Akt signaling pathways. PLoS One. 2017;12:e0184182.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Shynlova O, et al. Insulin-like growth factors and their binding proteins define specific phases of myometrial differentiation during pregnancy in the rat. Biol Reprod. 2007;76:571–8.CrossRefPubMed Shynlova O, et al. Insulin-like growth factors and their binding proteins define specific phases of myometrial differentiation during pregnancy in the rat. Biol Reprod. 2007;76:571–8.CrossRefPubMed
25.
Zurück zum Zitat Villani RM, et al. Patched1 inhibits epidermal progenitor cell expansion and basal cell carcinoma formation by limiting Igfbp2 activity. Cancer Prev Res (Phila). 2010;3:1222–34.CrossRef Villani RM, et al. Patched1 inhibits epidermal progenitor cell expansion and basal cell carcinoma formation by limiting Igfbp2 activity. Cancer Prev Res (Phila). 2010;3:1222–34.CrossRef
26.
Zurück zum Zitat Cen WN, et al. The expression and biological information analysis of miR-375-3p in head and neck squamous cell carcinoma based on 1825 samples from GEO, TCGA, and peer-reviewed publications. Pathol Res Pract. 2018;214:1835–47.CrossRefPubMed Cen WN, et al. The expression and biological information analysis of miR-375-3p in head and neck squamous cell carcinoma based on 1825 samples from GEO, TCGA, and peer-reviewed publications. Pathol Res Pract. 2018;214:1835–47.CrossRefPubMed
27.
Zurück zum Zitat Castel D, et al. Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes. Acta Neuropathol. 2015;130:815–27.CrossRefPubMedPubMedCentral Castel D, et al. Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes. Acta Neuropathol. 2015;130:815–27.CrossRefPubMedPubMedCentral
Metadaten
Titel
Seven genes for the prognostic prediction in patients with glioma
verfasst von
G.-H. Zhang
Q.-Y. Zhong
X.-X. Gou
E.-X. Fan
Y. Shuai
M.-N. Wu
G.-J. Yue
Publikationsdatum
14.02.2019
Verlag
Springer International Publishing
Erschienen in
Clinical and Translational Oncology / Ausgabe 10/2019
Print ISSN: 1699-048X
Elektronische ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-019-02057-3

Weitere Artikel der Ausgabe 10/2019

Clinical and Translational Oncology 10/2019 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.